Wednesday, May 23, 2018
 
 
Company News: Page (1) of 1 - 02/17/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
Further Data from Phase 1 Trial Reaffirms Favorable Tolerability of Single and Multiple Oral Doses of TD-1473 and Minimal Systemic Exposure in Healthy Subjects
(February 17, 2017)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:USA, Inc.,Medicine,Disease,medical technologists,Surgery,Children,Lifestyle,Family,Other,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Medical Fluid Bags Market will register 6.5% CAGR to cross USD 4.4 billion by 2024: Global Market Insights, Inc.
  • Longeveron Receives TEDCO Grant To Fund Stem Cell Research
  • Gross Revenue of Cancer Diagnostics Market will beat $156 Billion By 2024
  • Regenerative Medicine Market Analysis Study Found Huge Boom By Rising Prevalence Of Chronic Diseases And Genetic Disorders Till 2025: Grand View Research,Inc.

    Cancer
  • Xulon Press Announces the Release of the Blessings of Mrs. Clare's Hair Gratitude, Forgiveness, Guidance and Nurturance in Caring for People Who Are Not Easy to Love
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  • Achieve Life Sciences, Inc. Announces Reverse Stock Split
  • Accuray CyberKnife® Customer Achieves Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study
  • Check-Cap Announces Publication of CE Mark Multicenter Clinical Study Results on C-Scan® in Gut
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines